Biologic Treatment for Hidradenitis Suppurativa

Kelsey S. Flood, Martina L. Porter, Alexa B. Kimball*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Patients with hidradenitis suppurativa (HS) are often undertreated and there are limited efficacious therapies available for treating this population. Biologics are an emerging therapeutic modality used in the management of many inflammatory conditions including HS. Implementation of biologics is typically reserved for moderate-to-severe cases or in those cases that are refractory to treatment. Though many biologics have been trialed for use in HS, only one biologic, adalimumab, is currently US FDA (Food and Drug Administration) approved for the treatment of moderate-to-severe HS. Limitations in the use of biologics for HS include the many scoring systems utilized in research studies and the relatively few well-designed, adequately powered clinical trials.

Original languageEnglish (US)
Pages (from-to)625-638
Number of pages14
JournalAmerican Journal of Clinical Dermatology
Issue number5
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Biologic Treatment for Hidradenitis Suppurativa'. Together they form a unique fingerprint.

Cite this